AI Article Synopsis
- - The objective of the study was to evaluate the safety profile of linagliptin, a diabetes medication.
- - A systematic review of 16 clinical trials was performed, focusing on adverse events (AEs) compared to standard diabetes treatments, using data from medical databases like PubMed and Web of Science.
- - The most common AEs reported were nasopharyngitis and gastrointestinal issues, with approximately 14.9% in monotherapy and 17.6% in combination therapy, indicating that events ranged from mild to moderate in intensity.
Article Abstract
Objective: To describe the safety profile of linagliptin.
Methodology: Systematic review using PubMed/MEDLINE, BVS and Web of Science. The search strategy "Linagliptin" AND "safety" was used. The inclusion criteria were clinical trials with a control group composed of conventional DM2 pharmacotherapy.
Results: We identified 16 studies, and the most frequent adverse events (AEs) were nasopharyngitis with linagliptin at 5 and 10mg in monotherapy (31.6% and 29.6%, respectively) and gastrointestinal events (>10.0%) with linagliptin in combination. Of the AEs, 14.9 (±3.1)% were associated with the use of linagliptin in monotherapy, and 17.6 (±6.0)% in combination. The linagliptin AEs have a varied occurrence and frequency, ranging from mild to moderate intensity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pcd.2018.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!